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Abstract: Lactose intolerance related to primary or secondary lactase deficiency is
characterized by abdominal pain and distension, borborygmi, flatus, and diarrhea induced
by lactose in dairy products. The biological mechanism and lactose malabsorption is
established and several investigations are available, including genetic, endoscopic and
physiological tests. Lactose intolerance depends not only on the expression of lactase
but also on the dose of lactose, intestinal flora, gastrointestinal motility, small intestinal
bacterial overgrowth and sensitivity of the gastrointestinal tract to the generation of gas
and other fermentation products of lactose digestion. Treatment of lactose intolerance can
include lactose-reduced diet and enzyme replacement. This is effective if symptoms are only
related to dairy products; however, lactose intolerance can be part of a wider intolerance to
variably absorbed, fermentable oligo-, di-, monosaccharides and polyols (FODMAPs). This
is present in at least half of patients with irritable bowel syndrome (IBS) and this group
requires not only restriction of lactose intake but also a low FODMAP diet to improve
gastrointestinal complaints. The long-term effects of a dairy-free, low FODMAPs diet on
nutritional health and the fecal microbiome are not well defined. This review summarizes
recent advances in our understanding of the genetic basis, biological mechanism, diagnosis
and dietary management of lactose intolerance.
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1. Lactose and Lactase
Lactose is a disaccharide consisting of galactose bound to glucose and is of key importance in animal
life as the main source of calories from milk of all mammals, all except the sea lion. Intestinal absorption
of lactose requires hydrolysis to its component monosaccharides by the brush-border enzyme lactase.
From week 8 of gestation, lactase activity can be detected at the mucosal surface in the human intestine.
Activity increases until week 34 and lactase expression is at its peak by birth. The ability to digest
lactose during the period of breast-feeding is essential to the health of the infant as demonstrated by
congenital lactase deficiency that is fatal if not recognized very early after birth. However, following the
first few months of life, lactase activity starts to decrease (lactase non-persistence). In most humans, this
activity declines following weaning to undetectable levels as a consequence of the normal maturational
down-regulation of lactase expression [1]. The exceptions to this rule are the descendants of populations
that traditionally practice cattle domestication maintain the ability to digest milk and other dairy products
into adulthood. The frequency of this “lactase persistence trait” is high in northern European populations
(>90% in Scandinavia and Holland), decreases in frequency across southern Europe and the Middle East
(~50% in Spain, Italy and pastoralist Arab populations) and is low in Asia and most of Africa (~1% in
Chinese, ~5%–20% in West African agriculturalists); although it is common in pastoralist populations
from Africa (~90% in Tutsi, ~50% in Fulani) [2].
2. Genetics of Lactase Persistence
Lactase persistence is thought to be related to the domestication of dairy cattle during the last
10,000 years. Lactase persistence is inherited as a dominant Mendelian trait [3]. Adult expression of
the gene encoding lactase (LCT), located on 2q21 appears to be regulated by cis-acting elements [4].
A linkage disequilibrium (LD) and haplotype analysis of Finnish pedigrees identifies two single
single nucleotide polymorphisms (SNPs) associated with the lactase persistence trait: C/T-13910 and
G/A-22018, located ~14 kb and ~22 kb upstream of LCT, respectively, within introns 9 and 13 of the
adjacent minichromosome maintenance 6 (MCM6) gene [3]. The T-13910 and A-22018 alleles are 100%
and 97% associated with lactase persistence, respectively, in the Finnish study, and the T-13910 allele
is ~86%–98% associated with lactase persistence in other European populations [5–7]. The genotype in
China is C/C-13910, and no SNP associated with lactase persistence has been identified in the lactase
gene regulatory sequence [8,9]. However, there are several lactase gene single nucleotide polymorphisms
of this kind in other populations. Lactase persistence is mediated by G-13915 in Saudi Arabia [10],
in African tribes by the G-14010, G-13915, and G-13907 polymorphism (Figure 1) [11,12]. Thus,
lactase persistence developed several times independently in human evolution in different areas of the
world [11]. Multiple independent variants have allowed various human populations to quickly modify
LCT expression and have been strongly conserved in adult milk-consuming populations, emphasizing the
importance of regulatory mutations in recent human evolution [13]. In adult patients with homozygous
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lactase persistence, enzyme levels at the jejunal brush border are 10-times higher than for patients with
homozygous non-persistence, and heterozygous individuals [14].
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Figure 1. Map of the lactase (LCT) and minichromosome maintenance 6 (MCM6) gene 
region and location of genotyped single nucleotide polymorphisms (SNPs).  
(a) Distribution of 123 SNPs included in genotype analysis; (b) map of the LCT and MCM6 
gene region; (c) map of the MCM6 gene; and (d) location of lactase persistence-associated 
SNPs within introns 9 and 13 of the MCM6 gene in African and European populations [12]. 
3. Biological Mechanism of Lactose Intolerance 
About two thirds of the World’s population undergoes a genetically programmed decrease in lactase 
synthesis after weaning (primary lactase deficiency) [15,16]. Additionally, in individuals with lactase 
persistence the occurrence of gastrointestinal infection, inflammatory bowel disease, abdominal surgery 
and other health issues can also cause a decrease in lactase activity (secondary lactase deficiency). Both 
conditions must be distinguished from congenital lactase deficiency, which is an extremely rare disease 
of infancy with approximately 40 cases having been reported, mainly in Finland [2]. 
Whatever the cause, lactase deficiency results in unabsorbed lactose being present in the intestinal 
tract, which has effects that can lead to symptoms of lactose intolerance in susceptible individuals [17]. 
First, the increased osmotic load increases the intestinal water content. Second, lactose is readily 
fermented by the colonic microbiome leading to production of short chain fatty acids and gas (mainly 
hydrogen (H2), carbon dioxide (CO2), and methane (CH4)). These biological processes are present also 
for other poorly-absorbed, fermentable oligosaccharides, disaccharides, monosaccharides, and polyols 
(FODMAPs) that are ubiquitous in the diet [18,19]. Double-blind, cross-over studies in healthy 
volunteers applied scintigraphy or magnetic resonance imaging to document oro-cecal transit time 
together with breath testing to assess fermentation of the substrate. Fructose (a disaccharide similar to 
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region and location of genotyped single nucleotide polymorphisms (SNPs). (a) Distribution
of 123 SNPs included in genotype analysis; (b) map of the LCT and MCM6 gene region;
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3. Biological Mechanism of Lactose Intolerance
About two thirds of the World’s population undergoes a genetically programmed decrease in lactase
synthesis after weaning (primary lactase deficiency) [15,16]. Additionally, in individuals with lactase
persistence the occurrence of gastrointestinal infection, inflammatory bowel disease, abdominal surgery
and other health issues can also cause a decrease in lactase activity (secondary lactase deficiency). Both
conditions must be distinguished from congenital lactase deficiency, which is an extremely rare disease
of infancy with approximately 40 cases having been reported, mainly in Finland [2].
Whatever the cause, lactase deficiency results in unabsorbed lactose being present in the intestinal
tract, which has effects that can lead to symptoms of lactose intolerance in susceptible individuals [17].
First, the increased osmotic load increases the intestinal water content. Second, lactose is readily
fermented by the colonic microbiome leading to production of short chain fatty acids and gas (mainly
hydrogen (H2), carbon dioxide (CO2), and methane (CH4)). These biological processes are present
also for other poorly-absorbed, fermentable oligosaccharides, disaccharides, monosaccharides, and
polyols (FODMAPs) that are ubiquitous in the diet [18,19]. Double-blind, cross-over studies in healthy
volunteers applied scintigraphy or magnetic resonance imaging to document oro-cecal transit time
together with breath testing to assess fermentation of the substrate. Fructose (a disaccharide similar to
lactose) was seen to increase small bowel water, accelerate oro-caecal transit time (OCTT) and trigger a
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sharp increase in breath hydrogen production (Figure 2), whereas 30 g glucose (a well-absorbed control)
had no effect [20,21]. It should be noted that these effects are seen for poorly-absorbed, fermentable
disaccharides both in health and in patients with gastrointestinal disease [22–24]. Long-chain
carbohydrates (e.g., fructans, cellulose (“dietary fiber”)) that are not digested or absorbed by the small
intestine have less impact on small bowel transit than short-chain carbohydrates; however, fermentation
of this material in the large bowel produces similar effects on colonic function [21].
Malabsorption is a necessary precondition for lactose or FODMAP intolerance; however, the two
are not synonymous and the causes of symptoms must be considered separately [25]. The threshold
for dietary lactose tolerance is dependent on several factors including the dose consumed, residual
lactase expression [2], ingestion with other dietary components [26], gut-transit time, small bowel
bacterial overgrowth [22,23], and also composition of the enteric microbiome (e.g., high vs. low
fermenters, hydrogen vs. methane producers) [25,27–29]. In addition to these environmental and
physiological factors, it has been shown that patients with irritable bowel syndrome are at particular risk
of both self-reporting dairy intolerance [9,30] and experiencing symptoms after lactose and FODMAP
ingestion [31,32].
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Figure 2. Small bowel water content (SBWC) and breath hydrogen (H2) concentrations after 
drinking each of the drinks: glucose and fructose. The time of drinking (t = 0 min) is 
highlighted in the chart. Values of SBWC are mean volume (mL) ± s.e.m (standard error of 
mean). Values of H2 are mean concentration (p.p.m.) ± s.e.m. Figure modified from  
Murray et al. [21]. 
Symptoms of lactose intolerance generally do not occur until there is less than 50% of lactase activity. 
Regular lactose intake may also have an effect. Although lactase expression is not up-regulated by 
lactose ingestion, tolerance could be induced by adaptation of the intestinal flora [26]. Further, most 
people with lactase non-persistence can tolerate small amounts of lactose (less than 12 g, equivalent to 
 
Figure 2. Small bowel water content (SBWC) and breath hydrogen (H2) concentrations
after drinking each of the drinks: glucose and fructose. The time of drinking (t = 0 min) is
highlighted in the chart. Values of SBWC are mean volume (mL) ˘ s.e.m (standard error
of mean). Values of H2 are mean concentration (p.p.m.) ˘ s.e.m. Figure modified from
Murray et al. [21].
Symptoms of lactose intolerance generally do not occur until there is less than 50 of lactase activity.
Regular lactose intake may also have an effect. lthough lactase expression is not up-regulated by
lactose ingestion, tolerance could be induced by adaptation of the intestinal flora [26]. Further, most
people with lactase non-persistence can tolerate s all a ounts of lactose (less than 12 g, equivalent
to one cup), especially when it is combined with other foods or spread throughout the day [26,33].
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A double-blinded, randomized, three-way cross over comparison of lactose tolerance testing at 10 g,
20 g and 40 g lactose was performed in patients with diarrhea predominant irritable bowel syndrome
(IBS-D) and controls in a Chinese population with lactase deficiency [31]. The study design included
a dose below normal symptom threshold (10 g), plus a dose reflecting normal intake at a single meal
(20 g) and a “positive control” such as that used in epidemiological trials (40 g). The multiple-dose
method (Figure 3) not only demonstrates the effect of dose in both study groups, but also guides
nutritional management in a given patient. Importantly, the risk of symptoms in this study was greatly
increased in IBS-D patients, especially at low-moderate doses found in the diet [31]. Indeed, few
healthy controls with lactase non-persistence reported gastrointestinal (GI) symptoms except at the
40 g lactose dose [31]. IBS patients are known to be more sensitive to a variety of dietary and
physical interventions that distend the GI tract [34]. Further studies in the same Chinese population
demonstrated that anxiety, visceral hypersensitivity (defined by rectal barostat) and high-levels of gas
production on breath tests are associated with patient reports of symptoms after ingestion of a modest
(20 g) dose of lactose [35]. Heightened sensitivity to distension was associated with abdominal pain,
bloating and overall symptom severity. Excessive gas production contributed to digestive symptoms,
especially bloating and borborygmi [35]. Very interestingly, the same group of IBS patients that had
lactose intolerance on hydrogen breath testing also had heightened activity of the innate mucosal immune
system with increased counts of mast cells, intraepithelial lymphocytes and enterochrommafin cells in
the terminal ileum and right colon (Figure 4), with release of pro-inflammatory cytokines after lactose
ingestion [36]. These observations are similar to those seen in patients with post-infective IBS and
provide insight into the pathophysiological basis of food intolerance [37].
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Figure 3. Prevalence of lactose malabsorption (LM) and lactose intolerance (LI) in patients 
with diarrhea predominant irritable bowel syndrome (IBS-D) and controls at 10-, 20-, and 
40-g lactose hydrogen breath test (HBTs). * p < 0.05; ** p < 0.01 [31]. 
Another condition that may play a role in food tolerance is small intestinal bacterial overgrowth 
(SIBO) caused by abnormally high bacterial counts in the small intestine, exceeding 105 organisms/mL 
 
Figure 3. Prevalence of lactose malabsorption (LM) and lactose intolerance (LI) in patients
with diarrhea predominant irritable bowel syndrome (IBS-D) and controls at 10-, 20-, and
40-g lactose hydrogen breath test (HBTs). * p < 0.05; ** p < 0.01 [31].
Another condition that may play a role in food tolerance is small intestinal bacterial overgrowth
(SIBO) caused by abnormally high bacterial counts in the small intestine, exceeding 105
organisms/mL [38]. SIBO is clinically characterized by bloating, abdominal discomfort and diarrhea,
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symptoms that are very comparable to those of lactose intolerance [39]. Bacterial fermentation of lactose
with production of short-chain fatty acids and gas in the small bowel may be particularly likely to
trigger abdominal symptoms. Consistent with this hypothesis, combined scintigraphy and breath test
studies showed a higher prevalence of SIBO in IBS patients with lactose intolerance than in the lactose
malabsorption control group [22]. This effect appeared to be independent of oro-caecal transit time and
visceral sensitivity [22].
Nutrients 2015, 7 6 
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Figure 4. Representative photomicrographs showing tryptase positive mast cells (MCs) in 
the colonic mucosa of a healthy control (HCs) (a–c); an diarrhea predominant irritable bowel 
syndrome (IBS-D) patient with lactose malabsorption (LM) (d–f) and a patient with lactose 
intolerance (LI) (g–i). IBS-D patients with LI had increased mucosal MCs compared with 
LM and HCs [36]. 
4. Clinical Diagnosis of Lactose Malabsorption and Intolerance 
Problems with lactose absorption have been described, detected and diagnosed in several ways and 
this can lead to confusion among doctors and patients [26]. Lactase deficiency is defined as markedly 
reduced brush-border lactase activity relative to the activity observed in infants. Lactose malabsorption 
occurs when a substantial amount of lactose is not absorbed in the intestine. Because lactose 
malabsorption is nearly always attributable to lactase deficiency, the presence of this condition can be 
inferred from measurements of lactose malabsorption such as an increase of glucose in the blood or an 
increase of hydrogen in the breath. The term lactose intolerance is defined by patient reports of 
abdominal pain, bloating, borborygmi, and diarrhea induced by lactose. Less often it can present with 
 
Figure 4. Representative photomicrographs showing tryptase positive mast cells (MCs) in
the colonic mucosa of a healthy control (HCs) (a–c); an diarrhea predominant irritable bowel
syndrome (IBS-D) patient with lactose malabsorption (LM) (d–f) and a patient with lactose
intolerance (LI) (g–i). IBS-D patients with LI had increased mucosal MCs compared with
LM and HCs [36].
4. Clinical Diagnosis of Lactose alabsorption and Intolerance
Problems with lactose absorption have been described, detected and diagnosed in several ways
and this can lead to confusion among doctors and patients [26]. Lactase deficiency is defined as
markedly reduced brush-border lactase activity relative to the activity observed in infants. Lactose
malabsorption occurs when a substantial amount of lactose is not absorbed in the intestine. Because
lactose malabsorption is nearly always attributable to lactase deficiency, the presence of this condition
can be inferred from measurements of lactose malabsorption such as an increase of glucose in the blood
or an increase of hydrogen in the breath. The term lactose intolerance is defined by patient reports
of abdominal pain, bloating, borborygmi, and diarrhea induced by lactose. Less often it can present
with nausea or constipation and a range of systemic symptoms, including headaches, fatigue, loss of
Nutrients 2015, 7 8026
concentration, muscle and joint pain, mouth ulcers, and urinary difficulties [40,41]; however, it is unclear
whether these atypical symptoms are directly due to lactose ingestion, or related to the presence of
so-called “functional diseases”, such as irritable bowel syndrome (IBS), which is often accompanied
by multiple somatic complaints. Certainly, it is not possible to make a definitive diagnosis on clinical
presentation alone because double-blind trials have shown that the association of self-reported lactose
intolerance and the occurrence of symptoms after lactose ingestion are very poor [42], even in patients
with lactase deficiency (Figure 5) [9].
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Figure 5. Lack of agreement between objective and subjective assessment of lactose 
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There are various methods (Table 1) for diagnosing lactose malabsorption and intolerance [25]. 
Testing of lactase activity in mucosal biopsies from the duodenum is regarded as the reference standard 
for primary and secondary lactase deficiency [43], however, limitations include the inhomogeneous 
expression of lactase [44] and the invasiveness of the test. Genetic tests may be useful for identifying 
lactase persistence in some European populations as the T-13910 allele is ~86%–98% associated with 
lactase persistence in European populations [5–7], however other SNPs are present in Arabian and 
African populations [10–12]. Future genetic tests will likely cover a range of genetic polymorphisms, 
potentially eliminating this limitation. A further limitation of both biopsy and genetic tests is that no 
assessment of symptoms is made. This impacts on the clinical relevance of these investigations because, 
as addressed above, only a proportion of patients with lactase deficiency develop abdominal symptoms 
after ingesting lactose [31]. 
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potentially eliminati g this limitation. A further limitation of both biopsy and genetic tests is that no
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Table 1. Summary of tests for lactose malabsorption and lactose tolerance [25].
H2-Breath Test
[17,45]
Lactose
Tolerance
Test [46]
Genetic
Test [3,12]
Lactase Activity
at Jejunal Brush
Border [43,44]
Test principle
Increase of H2 in
respiratory air
after lactose
challenge
Increase of blood sugar
after lactose challenge
Genetic-13910C/T
polymorphism
Enzymatic activity
of lactase enzyme
in biopsy sample
Cut off
>20 ppm within 3
h
<1.1 mmol/L
within 3 h
C:C13910
lactase
non-persistence
<17–20 IU/g
Availability Good Excellent Variable Rare
False positives
(incorrect
diagnosis)
Rapid GI-transit,
small-intestinal
bacterial
overgrowth
Rapid GI-transit,
impaired glucose
tolerance
Rare (<5%) in
Caucasians
Probably rare
False negatives
malabsorption
wrongly excluded
Non-H2-producers.
Full colonic
adaptation
Fluctuations in
blood sugar
All causes of
secondary
lactose
malabsorption
Patchy enzyme
expression
Secondary causes
Cannot be
excluded, kinetic
of H2-increase
can be suggestive
Cannot
be excluded
Cannot be
excluded
Can be excluded
(histopathology at
same procedure)
Symptom
assessment
Possible Possible Not possible Not possible
Comment
Method of choice
for assessment of
lactose
malabsorption
and intolerance
Rarely performed due
to inferior sensitivity
and specificity
Definitive in
Caucasians.
Less in other
populations. Not
suitable in
secondary
lactase
deficiency.
Reference standard
for detection of
lactase deficiency
(primary or
secondary)
Cost Low Lowest High Highest
Lactose digestion and the association of maldigestion with symptoms can be assessed by the H2-breath
test [45] and the lactose tolerance test [46]; however, the former is confounded by fluctuations of
postprandial blood sugar. The H2-breath test can be false positive in the presence of small intestinal
bacterial overgrowth; however, a larger problem is false-negative tests due to the presence of hydrogen
non-producing bacteria in the colon (2%–43%) [17]. This problem of “hydrogen non-production” can
be mitigated to some extent by examining patient reports of symptoms after the test dose. Patients
Nutrients 2015, 7 8028
with “false positive” breath tests complain of symptoms directly after ingestion. Those with “true
positive” lactose intolerance complain of symptoms only after the substrate has entered the colon (usually
50–100 min). Another possibility is to combine the biopsy or genetic test (in Caucasians) with the
H2-breath test; however, this is an expensive and time-consuming approach.
5. Treatment of Lactose Intolerance
Treatment of lactose intolerance should not be primarily aimed at reducing malabsorption but rather at
improving gastrointestinal symptoms. Restriction of lactose intake is recommended because in blinded
studies patients with self-reported lactose intolerance, even those with IBS, can ingest at least 12 g
lactose without experiencing symptoms [26,47]. Even larger doses (15 to 18 g lactose) appear to be
tolerated when dairy products are taken with other nutrients [26]. One retrospective case review reported
improvement of abdominal discomfort, with lactose restriction in up to 85% of IBS patients with lactose
malabsorption [48]; however, prospective studies show that lactose restriction alone is not sufficient for
effective symptom relief in functional GI disease [49]. In our experience this approach is effective if
symptoms are related only to dairy products; however, in IBS patients, lactose intolerance tends to be
part of a wider intolerance to poorly absorbed, fermentable oligo-, di-, monosaccharides and polyols
(FODMAPs) [9,30]. Evidence from recent trials indicates that this is present in about half of patients
with IBS and this group requires not only restriction of lactose intake, but also a low FODMAP diet
to improve gastrointestinal complaints. An initial controlled trial of a diet low in FODMAPs reported
symptom improvement in 86% of IBS patients, compared to 49% for a standard dietary intervention [50].
Three randomized controlled trials have confirmed that a low FODMAP diet can benefit a wide range of
symptoms in IBS patients [32,51,52]. All these studies included lactose restriction in the early “strict”
phase of the dietary intervention; however, the specific role of lactose in causing symptoms was not
assessed. A major issue with almost all dietary intervention trials is that the contribution of individual
components (e.g. lactose) is difficult to assess as other dietary components (e.g., fat [53]) can also
produce symptoms and, potentially, confound results.
Lactase enzyme replacement is another important approach in patients with “isolated” lactose
intolerance that wish to enjoy dairy products. One double-blind, placebo-controlled, crossover
study shows that in lactose malabsorbers with intolerance, lactase obtained from Kluyveromyces
lactis represents a valid therapeutic strategy, with objective and subjective efficacy and without side
effects [54]. Exogenous lactase obtained from Aspergillus oryzae or from Kluyveromyces lactis breaks
down lactose into glucose and galactose to allow an efficient absorption [55].
A related strategy involves probiotics that alter the intestinal flora and may have beneficial effects in
IBS patients [56]. Four-week consumption of a probiotic combination of Lactobacillus casei Shirota
and Bifidobacterium breve Yakult improved symptoms and decreased hydrogen production in lactose
intolerant patients. These effects appeared to persist for at least three months after suspension of
probiotic consumption [56]. However, in another study, milk containing Lactobacillus acidophilus
did not consistently reduce gastrointestinal symptoms in patients with self-reported lactose intolerance
compared with control participants [26]. Further studies are required to provide high quality evidence to
support or compare the efficacy of these strategies.
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6. Long-Term Effects of Lactose or FODMAP Restriction
Although restricting dietary lactose or FODMAPs may improve gastrointestinal complaints,
long-term effects of a diet free of dairy or FODMAPs products may be of concern [57]. Dairy products
are the major source of calcium in many individuals. No study has addressed the safety and effectiveness
of calcium replacement for patients with lactose intolerance; however, it seems reasonable to recommend
increasing calcium intake from other foods or supplements in patients that restrict intake of dairy
products, especially in the presence of other risk factors for osteoporosis.
Diet also has effects on the colonic microbiome. Altering the dietary intake of FODMAPs alter
gastrointestinal microbiota [58] and a significant decrease in the concentration of probiotic bifidobacteria
after four weeks of a low FODMAP diet has been reported [52]. Whether this change has any long-term
implications is unknown. Recommending alternative foods is a key component of patient education and
even with dietetic advice nutrient intake, in particular of calcium, can be compromised on a low lactose,
low FODMAP diet.
Another issue that should be considered is the negative effect of dietary restriction on quality of
life [9,59]. Patients with self-reported lactose intolerance restrict intake not only of dairy products but
also of other foodstuffs due to general concerns about diet and health [9,59]. This is stressful and can be
expensive as shown by the recent trend to “gluten free diets” [60]. Moreover, if not properly supervised,
multiple food restrictions could lead to mal- or under-nutrition. Formal dietary intervention excludes a
wide range of potential dietary triggers for a short period to achieve symptom improvement, followed by
gradual food reintroduction to identify items and threshold doses that can be tolerated by patients.
7. Conclusions
Primary lactase deficiency can be regarded as the commonest “genetic disease” in the World,
although, in truth, loss of lactase expression in adulthood represents the normal “wild-type” and lactase
persistence the abnormal “mutant” state. Additionally, in secondary lactase deficiency, the ability to
digest lactose can be lost due to infection, surgery and other insults. Whatever the cause, lactose
malabsorption causes symptoms by several mechanisms: unabsorbed lactose leads to osmotic diarrhea;
products of its bacterial digestion lead to secretory diarrhea and gas can distend the colon. Diagnosis
of lactose malabsorption is based on detection either of the genetic mutation, loss of lactase activity
in the enteric mucosa or evidence of malabsorption in the blood or breath. However, the presence
of lactose malabsorption does not necessarily imply that abdominal symptoms are related to this
process. The majority of healthy individuals with lactase deficiency tolerate up to 20 g lactose without
difficulty. Instead, diagnosis of lactose intolerance requires concurrent assessment of lactose digestion
and abdominal symptoms.
Recent studies have provided important new insight into the complex relationship between lactase
deficiency, lactose malabsorption and symptom generation. This work has shed light on the
wider issue of food intolerance as a cause of symptoms in irritable bowel syndrome and related
conditions. Understanding the biological mechanism for food intolerance to lactose and FODMAPs
will help clinicians make a definitive diagnosis and guide rational dietary and medical management.
Ongoing studies will provide high quality evidence to document the efficacy and long-term effects of
these strategies.
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